A panel of experts recommended that the FDA approve donanemab, the newest experimental drug to treat Alzheimer’s disease. We asked experts how the rollout of a similar drug, the first to treat a root cause of the disease, has gone.
Source:
A panel of experts recommended that the FDA approve donanemab, the newest experimental drug to treat Alzheimer’s disease. We asked experts how the rollout of a similar drug, the first to treat a root cause of the disease, has gone.
Source: